Liqin Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Liqin Zheng has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Aijun Liu
Department of Anatomy, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, PR China
1 shared publication ChiHung Li
The International College, Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication- ChongZhi OuYang
Department of Lower Extremity Orthopedics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication - Chongkai Fang
Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication Chunmei Ma
School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
1 shared publicationHao Pan
School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
1 shared publication
Latest Publications
- Open Access
- 14 August 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102196
Light up the mitochondria: Smart tungstate-oligosaccharide nanoplatform orchestrates mitochondrial transfer from M2 macrophages to restore endothelial function for adaptive diabetic wound regeneration
- 14 August 2025
- Published by Elsevier in Materials Today Bio
- Vol. 34, 102196
Open AccessLight up the mitochondria: Smart tungstate-oligosaccharide nanoplatform orchestrates mitochondrial transfer from M2 macrophages to restore endothelial function for adaptive diabetic wound regeneration
- Open Access
- 11 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
The sustained-release agent of total flavonoids of Rhizoma drynariae prepared by nano-mesoporous silica can still promote osteogenesis and angiogenesis in vitro
Total flavonoids of Rhizoma drynariae (TFRD) possess the ability to enhance bone formation by promoting the coupling of angiogenesis and osteogenesis. However, the limited duration of serum concentration necessitates frequent oral administration. Designing TFRD as a sustained-release agent could enhance patient’s compliance and extend efficacy. Mesoporous silica nanoparticles (MSNPs) were used as a carrier for the preparation of a sustained-release agent containing TFRD (TFRD@MSNPs). Material characterization confirmed the successful loading of TFRD onto MSNPs. Subsequently, HUVECs were treated with varying concentrations of TFRD or TFRD@MSNPs to evaluate their effects on proliferation and migration ability. The secretion levels of VEGF, VCAM-1, EGF, TGF-β1, and type H endothelial markers (CD31 and EMCN) were assessed. BMSCs were cultured in conditioned medium derived from HUVECs induced by either TFRD or TFRD@MSNPs to evaluate their osteogenic potential in vitro. Gene expressions of ALP, OCN, and RUNX2, alkaline phosphatase activity, and calcium deposition were measured. The mass fraction of TFRD in the sustained release system TFRD@MSNP was approximately 60%. An appropriate concentration (< 400 µg/mL) of TFRD promoted the proliferation and migration of HUVECs, inhibited the secretion of TGF-β1, and increased the expression levels of VEGF, VCAM-1, EGF, CD31, and EMCN. The conditioned medium from HUVECs induced by TFRD significantly enhanced the osteogenic differentiation potential of BMSCs. An appropriate concentration of TFRD@MSNPs promoted the proliferation and migration of HUVECs, as well as the expression levels of CD31 and EMCN, but had no significant effect on VEGF, VCAM-1, EGF, or TGF-β1 secretion. The conditioned medium from HUVECs induced by TFRD@MSNPs increased ALP, OCN, and RUNX2 gene expression in BMSCs to varying degrees. Compared to the conditioned medium induced by TFRD in HUVECs, the conditioned medium induced by TFRD@MSNPs resulted in more calcium deposits in BMSCs. The sustained-release agent TFRD prepared by MSNPs can effectively promote the osteogenic differentiation of BMSCs through the coupling effect of angiogenesis and osteogenesis in vitro. These findings suggest that using MSNPs to formulate TFRD as sustained-release agent holds potential for clinical application, but the specific mechanism remains to be elucidated.
- 11 February 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-15
Open AccessThe sustained-release agent of total flavonoids of Rhizoma drynariae prepared by nano-mesoporous silica can still promote osteogenesis and angiogenesis in vitro
Total flavonoids of Rhizoma drynariae (TFRD) possess the ability to enhance bone formation by promoting the coupling of angiogenesis and osteogenesis. However, the limited duration of serum concentration necessitates frequent oral administration. Designing TFRD as a sustained-release agent could enhance patient’s compliance and extend efficacy. Mesoporous silica nanoparticles (MSNPs) were used as a carrier for the preparation of a sustained-release agent containing TFRD (TFRD@MSNPs). Material characterization confirmed the successful loading of TFRD onto MSNPs. Subsequently, HUVECs were treated with varying concentrations of TFRD or TFRD@MSNPs to evaluate their effects on proliferation and migration ability. The secretion levels of VEGF, VCAM-1, EGF, TGF-β1, and type H endothelial markers (CD31 and EMCN) were assessed. BMSCs were cultured in conditioned medium derived from HUVECs induced by either TFRD or TFRD@MSNPs to evaluate their osteogenic potential in vitro. Gene expressions of ALP, OCN, and RUNX2, alkaline phosphatase activity, and calcium deposition were measured. The mass fraction of TFRD in the sustained release system TFRD@MSNP was approximately 60%. An appropriate concentration (< 400 µg/mL) of TFRD promoted the proliferation and migration of HUVECs, inhibited the secretion of TGF-β1, and increased the expression levels of VEGF, VCAM-1, EGF, CD31, and EMCN. The conditioned medium from HUVECs induced by TFRD significantly enhanced the osteogenic differentiation potential of BMSCs. An appropriate concentration of TFRD@MSNPs promoted the proliferation and migration of HUVECs, as well as the expression levels of CD31 and EMCN, but had no significant effect on VEGF, VCAM-1, EGF, or TGF-β1 secretion. The conditioned medium from HUVECs induced by TFRD@MSNPs increased ALP, OCN, and RUNX2 gene expression in BMSCs to varying degrees. Compared to the conditioned medium induced by TFRD in HUVECs, the conditioned medium induced by TFRD@MSNPs resulted in more calcium deposits in BMSCs. The sustained-release agent TFRD prepared by MSNPs can effectively promote the osteogenic differentiation of BMSCs through the coupling effect of angiogenesis and osteogenesis in vitro. These findings suggest that using MSNPs to formulate TFRD as sustained-release agent holds potential for clinical application, but the specific mechanism remains to be elucidated.
- 20 November 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (3) , e2302256
Controllable Adaptive Molybdate‐Oligosaccharide Nanoparticles Regulate M2 Macrophage Mitochondrial Function and Promote Angiogenesis via PI3K/HIF‐1α/VEGF Pathway to Accelerate Diabetic Wound Healing
The complex wound environment of diabetic wounds leads to poor treatment efficacy, and the inflammatory disorders and vascular injury are the primary causes of death in such patients. Herein, a sprayable, controllable adaptive, pH‐responsive nanosystem of molybdate and oligosaccharide (CMO) is specially developed as an immunomodulatory and angiogenesis‐promotion material for diabetic wound healing. CMO exhibited pH‐responsive release of Mo2+ and oligosaccharide (COS), specifically in response to the alkalescent environment observed in diabetic wounds. CMO provide an anti‐inflammatory environment by promoting M2 polarization through significantly stimulating macrophage mitochondrial function. Specifically, CMO with a certain concentration reduce reactive oxygen species (ROS) and tumor necrosis factor α (TNF‐α) expression, and upregulated mitochondrial membrane potential (MMP), superoxide dismutase (SOD), and interleukin 10 (IL‐10) expression in macrophages. Moreover, CMO facilitate angiogenesis via upregulating the PI3K/HIF‐1α/VEGF pathway—a critical process for the formation of new blood vessels that supply nutrients and oxygen to the healing tissue. Remarkably, CMO promote cell viability and migration of endothelial cells, and enhance the expression of angiogenic genes. In vitro and in vivo studies suggest this simple but powerful nanosystem targeting mitochondrial function has the potential to become an effective treatment for diabetic wound healing.
- 20 November 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (3) , e2302256
Controllable Adaptive Molybdate‐Oligosaccharide Nanoparticles Regulate M2 Macrophage Mitochondrial Function and Promote Angiogenesis via PI3K/HIF‐1α/VEGF Pathway to Accelerate Diabetic Wound Healing
The complex wound environment of diabetic wounds leads to poor treatment efficacy, and the inflammatory disorders and vascular injury are the primary causes of death in such patients. Herein, a sprayable, controllable adaptive, pH‐responsive nanosystem of molybdate and oligosaccharide (CMO) is specially developed as an immunomodulatory and angiogenesis‐promotion material for diabetic wound healing. CMO exhibited pH‐responsive release of Mo2+ and oligosaccharide (COS), specifically in response to the alkalescent environment observed in diabetic wounds. CMO provide an anti‐inflammatory environment by promoting M2 polarization through significantly stimulating macrophage mitochondrial function. Specifically, CMO with a certain concentration reduce reactive oxygen species (ROS) and tumor necrosis factor α (TNF‐α) expression, and upregulated mitochondrial membrane potential (MMP), superoxide dismutase (SOD), and interleukin 10 (IL‐10) expression in macrophages. Moreover, CMO facilitate angiogenesis via upregulating the PI3K/HIF‐1α/VEGF pathway—a critical process for the formation of new blood vessels that supply nutrients and oxygen to the healing tissue. Remarkably, CMO promote cell viability and migration of endothelial cells, and enhance the expression of angiogenic genes. In vitro and in vivo studies suggest this simple but powerful nanosystem targeting mitochondrial function has the potential to become an effective treatment for diabetic wound healing.